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To understand the differential expression of epitopes on monomeric and oligomeric forms of the envelope glycoproteins,
nine human monoclonal antibodies (mAbs) were derived from the cells of human immunodeficiency virus-infected subjects
by selection with soluble oligomeric gp140 (o.140). These nine mAbs and 12 human mAbs selected with V3 peptides, viral
lysates, and rgp120, specific for the V2, V3, C5, CD4-binding domain (CD4bd), and gp41, were tested in a binding assay to
compare the exposure of these regions on monomeric gp120 or gp41 and on o.140. None of the 21 mAbs were oligomer
specific. However, mAbs to V3 and CD4bd were “oligomer sensitive,” whereas mAbs to V2 and the distal epitope of C5 tended
to be “monomer sensitive” (i.e., to react better with the oligomer or monomer, respectively). The majority of anti-gp41 mAbs
reacted similarly with monomer and oligomer. Although the uncleaved o.140 used in this study differs from the cleaved
gp120/41 oligomer found on the native virus particle, these results suggest that new epitopes are not introduced by
oligomerization of viral envelope proteins, that such oligomer-specific epitopes, if they exist, are not highly immunogenic,
and/or that they are not efficiently selected using soluble o.140. © 2000 Academic Press
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The envelope proteins of HIV-1, like those of many
other retroviruses and enveloped viruses, exist in their
native form as oligomers (Doms and Helenius, 1986;
Einfeld and Hunter, 1988; Pinter and Fleissner, 1979;
Pinter et al., 1989). Trimers and tetramers of gp41 were
detected in viral lysates of T cell line-adapted human
immunodeficiency virus type 1 (HIV-1) by immunoprecipi-
tation (Pinter et al., 1989), and recent biophysical analy-
ses of recombinant protein fragments of the gp41
ectodomain revealed the gp41 structure as an a-helical
trimeric complex (Lu et al., 1995). Further crystallo-
raphic studies of two fragments from the gp41 ectodo-
ain confirmed their association into trimers (Chan et al.,
997; Weissenhorn et al., 1997). The formation of hetero-
oligomeric complexes of gp120/41 as the HIV-1 virion
assembles presumably causes quaternary structural
changes that could lead to new antigenic properties
compared with those displayed by monomeric forms of
these molecules (Hurtley and Helenius, 1989).
The physical and immunologic effects of oligomeriza-
tion have implications for vaccine development and for
the study of the immune response against HIV-1. This
has been investigated in studies of oligomeric forms of
the HIV-1 envelope glycoproteins. Thus oligomeric forms
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220of the uncleaved envelope precursor display enhanced
reactivity with HIV-1 sera and/or monoclonal antibodies
(mAbs) compared with monomeric gp120 (m.120) (Rich-
ardson et al., 1996; VanCott et al., 1995). Moreover, im-
munization of rabbits with oligomeric gp140 (o.140) pro-
duced high-titered serum Abs that preferentially bound to
epitopes exposed on the native forms of gp120 and
gp160 and neutralized both T cell line-adapted (TCLA)
and primary isolates of HIV-1 (VanCott et al., 1997). In
another vaccine study, immunization with a subunit con-
sisting of simian immunodeficiency virus (SIV) gp130
oligomers, but not gp130 monomers, protected rhesus
macaques against infection with SIVmac32H (Luke et al.,
1996; Petry et al., 1998). A vaccine regimen consisting of
recombinant canarypox-HIVgp160MN and rgp120SF2, which
primes the immune response with the HIV glycoproteins
in the context of a virus envelope, induced serum Abs in
healthy individuals that neutralized some primary iso-
lates (Clements-Mann et al., 1998; Zolla-Pazner et al.,
1997, 1998b). The administration of a similar “prime/
boost” vaccine regimen to chimpanzees, consisting of
recombinant adenovirus containing a gp160 insert from
HIVMN followed by a boost of rgp120SF2, also resulted in
he induction of Abs neutralizing T cell line-adapted and
ome primary isolates (Zolla-Pazner et al., 1998a). Thus
onstructs or proteins that approximate native oligomeric
tructures of the SIV and HIV virus envelope can induce
rotection and elicit neutralizing Abs. In the case of
himpanzees, the presence of these Abs correlates with
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221EFFECTS OF OLIGOMERIZATION ON HIV-1 ENVELOPE EPITOPESprotection from virus challenge (Lubeck et al., 1997;
olla-Pazner et al., 1998a).
Although soluble uncleaved oligomeric forms of the en-
velope precursor, such as o.140, are not exact representa-
tions of the membrane-associated, cleaved, and nonco-
valently associated gp120/gp41 complex of the intact virion,
a variety of studies (including those summarized earlier and
later) suggest that o.140 is a biologically more relevant form
of the envelope than m.120 and might display new epitopes
conferred by altered conformation and/or exposure of new
immunogenic regions. For example, several murine mAbs
elicited by immunization with o.140 recognize o.140 but not
m.120 or gp140 (Broder et al., 1994). Until now, however, no
oligomer-specific Abs have been described in humans.
Only “oligomer-sensitive” human Abs, which preferentially
bind to oligomers rather than to monomers, have been
found (Pinter et al., 1989; Poumbourios et al., 1992).
This study was designed, therefore, to select human
mAbs with o.140 to determine whether human mAbs to
oligomer-specific antigens could be identified. The re-
sults do not provide support for the existence of oli-
gomer-specific Abs or for epitopes on o.140 that are
unique. However, several categories of mAbs were de-
fined on the basis of their preferential binding to mono-
mers or to oligomers. The existence of oligomer-sensi-
tive mAbs derived from the cells of humans infected with
HIV-1 demonstrates that oligomeric structures of HIV, as
well as monomeric forms of the envelope glycoproteins,
serve as immunogens in vivo.
RESULTS
Generation of human mAbs using oligomeric gp140
Oligomeric gp140 was used to select nine mAbs (Table
) specific for six regions, including epitopes in V2, V3,
D4bd, and C5 of gp120 and epitopes in clusters I and II of
p41 (described in Olshevsky et al., 1990; Rusche et al.,
988; Shotton et al., 1995; Xu et al., 1991). Three mAbs,
T
Characteristics of Human mAb
mAb Isotype Specificity
1357 IgG1k V2 Block the binding o
1361 IgG1k V2 protein from whic
1334 IgG1l V3 Binds to the V3 pep
1331E IgG1k CD4bd Inhibits binding of s
1331A IgG3l C5 Core epitope localiz
overlapping C-ter
1367 IgG1l gp41-I Reactive with rgp41
1281 IgG1l gp41-II Reactive with gp41,
1342 IgG1l gp41-II recombinant prot
1379 IgG1l gp41-II331A, 1331E, and 1361, were derived from two blood sam-
les of one HIV-infected individual, whereas the remaining
n
mAbs were each generated from different individuals. Most
f the mAbs, seven of nine, were conformation dependent.
hese seven mAbs reacted with recombinant proteins but
id not bind to denatured o.140 or m.120 (anti-gp120 mAbs:
357, 1361, and 1331E) and did not react with gp41 peptides
anti-gp41 mAbs: 1281, 1342, 1367, and 1379). Only two
Abs, 1334 and 1331A, were directed to linear epitopes
nd reacted with V3 and C5 peptides, respectively. The
pecificities of the mAbs selected on o.140 were deter-
ined in various assays summarized in Table 1. Briefly, two
nti-V2 mAbs, 1357 and 1361, had similar specificities as did
he other anti-V2 mAb, 697-D, which was previously de-
cribed (Gorny et al., 1994). Both mAbs blocked binding of
biotinylated 697-D to gp120LAI and did not react with the
PR6 protein, a recombinant form of gp120BH10 that lacks the
V1/V2 region (Jeffs et al., 1996). Anti-V3 mAb 1334 cross-
reacted with several V3 peptides from clade B strains,
including MN, SF2, SC, NY/5, and CDC4. Another study
showed that this mAb was also cross-reactive with the V3
peptides from clades A, C, D, F, G, and H (Zolla-Pazner et al.,
1999). The specificity of anti-CD4bd mAb 1331E was deter-
mined in a functional assay. This mAb inhibited the binding
of soluble CD4 to gp120LAI, activity that was similar to that of
everal anti-CD4bd mAbs previously described (Kar-
owska et al., 1992). Anti-C5 mAb 1331A was specific for an
pitope in the region of amino acids (aa) 510–516 on the
asis of binding to two overlapping C-terminus peptides: aa
87–509 and 495–516.
Among the anti-gp41 mAbs, 1367 was specific for
luster I epitopes that span aa 590–600, and three mAbs,
281, 1342, and 1379, were reactive with cluster II
pitopes (aa 644–663), as recently described (Gorny
t al., submitted for publication).
Binding of mAbs to monomer and oligomer
As shown in Figs. 1 and 2, each of the nine mAbs
elected with o.140 also bound to m.120 or to m.41, but
ted Using Oligomeric gp140451
Characteristics
ylated anti-V2 mAb 697-D to rgp120LAI and do not react with the PR6
1/V2 region has been deleted
f MN, SF2, NY/5, RF, and CDC4 strains
CD4 to rgp120LAI
egion aa 510–516 (VVQREKR) of rgp120LAI based on binding to
peptides
7–647)
g to a region within aa 647–682 based on reactivity with overlapping
gp41ABLE 1
s Selec
f biotin
h the V
tides o
oluble
ed to r
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(aa 56
bindinone reacted uniquely with o.140. Twelve additional hu-
an mAbs were similarly examined; these were specific
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222 GORNY ET AL.for the same six regions that were recognized by the nine
mAbs selected on o.140. The 12 aforementioned mAbs
had been selected previously using V3 peptides of MN
FIG. 1. Binding of anti-gp120 mAbs to monomeric gp120451 (left graph
tested: anti-V2 (a and b), anti-V3 (c and d), anti-CD4bd (e and f), and an
Asterisks indicate the mAbs selected with o.140. Each graph represent
from several experiments are presented in Table 2.and RF, rgp120LAI, or viral lysates from HIVIIIB. In the
xperiments shown in these figures, the amount of mAb ieeded to achieve half-maximal binding by these mAbs
as calculated by titrating the mAbs against a constant
mount of antigen.
o oligomeric gp140451 (right graphs). Four groups of human mAbs were
510-516 (g and h). M.120 and o.140 were coated onto plates at 10 nM.
nding curve from one assay. The average half-maximal binding valuess) and t
ti-C5 aaTables 2 and 3 summarize the binding results, show-
ng the average values from three or four experiments, of
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223EFFECTS OF OLIGOMERIZATION ON HIV-1 ENVELOPE EPITOPESmAb concentrations required for half-maximal binding to
monomer and oligomer. The lower the concentration of
mAb to achieve half-maximal binding, the higher is the
relative affinity. For example, anti-CD4bd mAb 729-D has
a higher relative affinity to o.140 than to m.120 as shown
by the half-maximal binding values for the two proteins,
0.03 and 0.39 mg/ml, respectively (Table 2). Ratios calcu-
ated as the half-maximal binding for m.120 or m.41 to the
alf-maximal binding for o.140 are used to show prefer-
FIG. 2. Reactivity of anti-gp41 mAbs with monomeric gp41IIIB spanning
pecific for parvovirus B19, was used as a negative control. All other
TABLE 2
Binding of mAbs to Monomeric gp120
and Oligomeric gp140 Glycoproteins
mAb Specificity
Half-maximal binding to: Ratio of
m.120/o.140
valuesm.120451
a o.140451
a
697-D V2 0.08 6 0.02b 0.14 6 0.04b 0.5
1357c V2 0.12 6 0.03 0.27 6 0.07 0.4
1361c V2 0.07 6 0.01 0.13 6 0.04 0.5
447-52D V3 0.18 6 0.05 0.017 6 0.006 10.5
838-D V3 0.31 6 0.06 0.043 6 0.029 7.2
1334c V3 0.2 6 0.07 0.023 6 0.006 8.6
559/64-D CD4bd 0.14 6 0.05 0.03 6 0.01 4.6
654-D CD4bd 0.38 6 0.12 0.04 6 0.01 9.5
729-D CD4bd 0.39 6 0.06 0.03 6 0.02 13.0
9CL CD4bd 0.73 6 0.07 0.08 6 0.01 9.1
1331Ec CD4bd 0.24 6 0.05 0.05 6 0.01 4.8
858-D C5 0.01 6 0.003 0.06 6 0.01 0.2
989-D C5 0.01 6 0.009 0.11 6 0.2 0.1
1331Ac C5 0.004 6 0.002 0.03 6 0.01 0.1
a m.120 and o.140 were coated onto plastic plates at 10 nM.
b 50% maximal binding values in mg/ml; means of three or fourexperiments 6 SD.
c mAbs selected using o.140451.ntial binding to oligomer (.1.0) or to monomer (,1.0).
or mAb 729-D, the ratio value is 13.0, demonstrating the
trong binding preference for the oligomer.
Each group of mAbs, defined by their specificities, was
ound to possess a characteristic binding preference,
hich indicates the relative exposure on monomers ver-
us oligomers of the particular epitope for which each
roup of mAbs is specific. The distribution of binding
atios is displayed in Fig. 3 and distinguishes the anti-
p120 mAbs into two sets: the ratios for the V2- and
5-specific mAbs are in the range of 0.1 to 0.5 and are
eparated by an order of magnitude from the binding
atios of the V3- and CD4bd-specific mAbs. These data
-757 (a) and oligomeric gp140 from HIVIIIB (b). The human mAb 860-55D,
tion is as in the legend to Fig. 1.
TABLE 3
Binding of mAbs to Monomeric gp41
and Oligomeric gp140 Glycoproteins
mAb
Epitope
specificity
within gp41
Half-maximal binding to:
Ratio of
m.41/o.140m.41IIIB
a o.140IIIB
a
50-69 Cluster Ib 0.092 6 0.017c 0.017 6 0.001 5.4
1367d Cluster I 0.023 6 0.004 0.02 6 0.001 1.1
98-6 Cluster II 0.046 6 0.021 0.027 6 0.007 1.7
167-D Cluster II 0.033 6 0.012 0.027 6 0.007 1.2
1281d Cluster II 0.032 6 0.019 0.034 6 0.011 0.9
342d Cluster II 0.048 6 0.019 0.032 6 0.008 1.5
379d Cluster II 0.023 6 0.001 0.027 6 0.002 0.8
a m.41 and o.140 were coated onto plastic plates at 10 nM.
b Cluster I occurs between aa 590 and 600; cluster II occurs between
aa 644 and 663.
c 50% maximal binding values in mg/ml, means of three experi-ments 6 SD.
d mAbs selected using o.140451.
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224 GORNY ET AL.suggest that the anti-V2 and anti-C5 mAbs preferentially
bind to the monomeric form (are “monomer sensitive”)
whereas anti-V3 and -CD4bd mAbs preferentially bind to
o.140 (are “oligomer sensitive”).
For the experiments with the anti-gp41 mAbs, half-
maximal binding values were compared for m.41 (a re-
combinant gp41 from HIVIIIB spanning aa 517–757) and
for o.140 from HIVIIIB. MAbs specific for two regions of
gp41, cluster I (spanning aa 590–600) and cluster II
(spanning aa 644–663) (Xu et al., 1991), selected using
o.140, were compared with three mAbs to the same
epitope clusters that had been selected with viral lysates
(Fig. 2 and Table 3). The majority of gp41 mAbs displayed
binding ratios ranging from 0.8 to 1.7 (Table 3 and Fig. 3),
between the two sets of anti-gp120 mAbs, denoting
equivalent binding to both m.120 and o.140. Only one
mAb, 50–69, selected with a detergent-lysed preparation
of HIVIIIB and specific for cluster I, was oligomer sensi-
ive, displaying the highest binding ratio of 5.4.
None of the anti-envelope mAbs studied were oli-
omer specific, suggesting that if any new gp120- or
p41-associated epitopes were formed on assembly of
oluble gp160 into oligomers, they did not represent
ighly immunogenic structures that exist in vivo. The
data presented in Figs. 1 and 2 and Tables 2 and 3 also
suggest that the method of selecting the anti-envelope
mAbs did not affect their monomer or oligomer sensitiv-
ity, because the method of selection did not determine
this characteristic of the resultant mAbs.
DISCUSSION
FIG. 3. Distribution of binding ratio of anti-gp120 and anti-gp41 mAb
a given mAb for m.120 or m.41 divided by the half-maximal binding forOligomeric gp140 is an uncleaved molecule that is not
associated with the membrane structure of the infectedcell or with the lipid envelope of the virion. Thus although
o.140 forms oligomers, as does the native gp160 mole-
cule, this uncleaved precursor is known to differ from the
membrane-expressed, cleaved, and noncovalently asso-
ciated gp120/gp41 complex. Indeed, some differences in
the binding of mAbs to o.140 and to intact virions have
been observed: although V3 and C5 structures are well
exposed on both o.140 and intact virions, epitopes in
cluster II near the transmembrane domain of gp41 and,
in particular, epitopes in the CD4bd of gp120 are poorly
expressed on virions in contrast to o.140 (Nyambi et al.,
1998). Similarly, antigenic differences have been noted
between monomeric and oligomeric versions of gp120
(Richardson et al., 1996; VanCott et al., 1995), and these
have formed the rationale for the use of o.140 animal
vaccine trials (VanCott et al., 1998, 1997) and for the
hypothesis that o.140 would serve as a preferred vaccine
construct relative to m.120 (VanCott et al., 1997). This,
then, prompted this more thorough investigation of the
differential antigenic nature or the monomeric and oligo-
meric forms of the HIV envelope glycoproteins.
Selection of human anti-HIV mAbs by screening for re-
activity with o.140 resulted in the generation of nine mAbs
with specificities to six previously known envelope do-
mains: V2, V3, CD4bd and C5 of gp120, and clusters I and
II of gp41. None of these mAbs were oligomer specific
(i.e., none reacted solely with oligomeric forms of the pro-
teins). Although these data cannot rule out the existence of
oligomer-specific epitopes, they do indicate that if present,
these epitopes are not as immunogenic as the six envelope
regions recognized by existing human mAbs.
ing ratios were defined as the quotient of the half-maximal binding ofOligomer-specific epitopes have been described on
the basis of their reactivity with murine mAbs (Broder et
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225EFFECTS OF OLIGOMERIZATION ON HIV-1 ENVELOPE EPITOPESal., 1994; Earl et al., 1994). It is notable that these murine
Abs were made from the spleens of mice 6–9 weeks
fter they had been immunized. In contrast, human anti-
IV mAbs are normally derived from the cells of HIV-
nfected individuals several years after infection. Such
hronic stimulation, present during the course of HIV-1
nfection, leads to increased Ab reactivity, as has been
emonstrated with countless antigens, including gp120
Gorny et al., 1997). It is possible, therefore, that as with
he mouse, oligomer-specific Abs could exist in humans
arly after initial antigenic stimulation but that later in
nfection, these antibodies may also react with mono-
ers. Data supporting this hypothesis were reported by
anCott et al. (1995), who showed that Abs in HIV-posi-
tive sera reactive with o.140 appeared earlier than those
reactive with m.120, suggesting that early in the infection,
oligomer-specific Abs may exist.
All 21 tested anti-envelope mAbs react with both
monomers and oligomers by ELISA, but the preference in
binding to monomer or oligomer depends on the epitope
for which the mAb is specific. Three groups of mAbs can
be defined on the basis of monomer vs. oligomer pref-
erence. The anti-V3 and CD4bd mAbs are “oligomer sen-
sitive,” a term defined by Broder et al. (1994) to refer to
significantly better reactivity with oligomer than mono-
mer. Such reactivity suggests that the epitopes recog-
nized by these mAbs are better exposed on the oligo-
meric than the monomeric structure. The mAbs to V2 and
the distal epitope of C5 are “monomer sensitive.” These
data suggest that these epitopes may be partially oc-
cluded on oligomer formation. Finally, most of the anti-
gp41 mAbs are “oligomer independent.” These mAbs
react equally with m.41 and o.140; their reactivity sug-
gests that these epitopes are exposed comparably on
the monomeric and oligomeric structures.
The interaction of bivalent mAbs with monomeric an-
tigens (m.120 and m.41) will be quantitatively different
than that between bivalent mAbs and multimeric antigen
(o.140). For example, antigen oligomerization might in-
crease the likelihood of mAb binding to two molecules
associated in an oligomer compared with the probability
that mAb would bind to two nonassociated monomers.
Such a result could lead to steeper binding curves with
oligomers and, consequently, to higher binding affinities
for oligomers than for monomers. Despite this theoretical
possibility, this did not seem to play a pivotal role in the
studies described here. Although anti-V3 and -CD4bd
mAbs bound better to oligomers than to monomers,
anti-V2 and anti-C5 mAbs, bound preferably to mono-
mers, indicating that under the conditions used here, the
valency of the epitope was not as important as its avail-
ability on the two different forms of the envelope mole-
cule. Furthermore, a solid-phase format was used, in
which monomer and oligomer were coated onto plastic
at equimolar concentrations; these conditions restrict
antigen flexibility and lattice formation, which would have
o
oplayed a more critical role in liquid phase. Factors that
may have affected the better binding of V3- and CD4bd-
specific mAbs to oligomers are thought to include con-
formational changes that occur on oligomerization,
which may enhance accessibility and proximity of the V3
and CD4bd epitopes in the oligomeric structure.
Because the oligomeric glycoprotein may be a more
physiological representation of the native envelope
structure on the virus particle, the binding of an mAb to
this protein may be a good indicator of neutralizing
activity. Indeed, the neutralization of primary isolate
HIVJR-FL by human mAbs correlated with the relative af-
inity of anti-V3 mAb 447-52D and other mAbs for the
ligomeric envelope expressed on the surface of trans-
ected 293 cells (Fouts et al., 1997). The assay distin-
uished neutralizing from non-neutralizing mAbs on the
asis of binding (Fouts et al., 1997). Further study, how-
ver, indicated that certain mAbs recognize epitopes on
he oligomeric envelope glycoproteins in a binding assay
ut do not neutralize the virus (Fouts et al., 1998). This
onfirms other observations that human anti-C5 mAbs
hat have no neutralizing activity bind well to intact viri-
ns, as shown in a newly developed capture assay
Nyambi et al., 1998). Thus binding to the oligomeric
nvelope proteins on the virion is not a sole criterion for
irus neutralization. Neutralization occurs as a function
f several factors, including virus binding, Ab specificity,
nd Ab affinity or avidity; indeed, this has been docu-
ented for many anti-HIV mAbs (Gorny et al., 1993;
angedijk et al., 1991; Nakamura et al., 1993; Parren et
l., 1998; VanCott et al., 1994).
The fact that two important neutralizing regions, the V3
oop and CD4bd, are better exposed on o.140 than on
.120 suggests the possibility that the oligomeric protein
ay serve as an improved vaccine immunogen. A few
tudies have shown that immunization of rabbits with
ligomeric proteins elicited Abs that neutralized HIV-1
rimary isolates or protected rhesus macaques against
IV challenge, whereas monomeric proteins had no such
ffect (Luke et al., 1996; Petry et al., 1998; VanCott et al.,
997). It is, as yet, unknown whether this effect of immu-
ization with oligomer resulted from a quantitatively bet-
er immune response or depended on a qualitatively
ifferent character of the elicited response.
In conclusion, none of the mAbs selected with o.140
roved to be oligomer specific. Moreover, the use of
.140 did not select for anti-gp120 or anti-gp41 mAbs with
ubstantially different characteristics than those se-
ected with m.120, V3 peptides, or viral lysate. The stud-
es suggest, however, that most of gp41 epitopes are
qually well exposed on oligomer and monomer, that the
2 and distal epitope of C5 are less well exposed on the
ligomer, and that V3 and the CD4bd are better exposed
n the oligomer.
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226 GORNY ET AL.MATERIALS AND METHODS
HIV-infected subjects
Peripheral blood mononuclear cells were separated
from the blood of asymptomatic HIV-1-infected individu-
als. The subjects had been seropositive for several years
and had CD41 cells above 500/mm3. Each subject gave
informed consent to participate in the study.
Monoclonal and polyclonal antibodies
The human mAbs against envelope proteins of HIV-1
were produced according to the method previously de-
scribed (Gorny, 1994; Gorny et al., 1991). Briefly, periph-
eral blood mononuclear cells were transformed with Ep-
stein–Barr virus. The cells were cultured for 3–4 weeks,
and the culture supernatants screened for reactivity
against o.140. Cells from reactive cultures were subse-
quently fused with the human 3 mouse heteromyeloma
SHM-D33 (Teng et al., 1983), and the resulting hybrid-
omas were cloned at limiting dilution until monoclonality
was achieved. Nine human mAbs were generated by this
selection method. The methods by which their specific-
ities were defined are described later, and their charac-
teristics are listed in Table 1.
Twelve additional human mAbs were also used in this
study. These mAbs had been selected using V3 peptides
of MN or RF, viral lysate from HIVIIIB, or recombinant
onomeric gp120 of LAI. Those previously described
Abs include anti-V2 mAb 697-D, selected with recom-
inant gp120LAI (Gorny et al., 1994), anti-V3 mAbs 447-
52D and 838-D, selected with V3 peptides from MN and
RF, respectively (Gorny et al., 1993; VanCott et al., 1994),
anti-CD4bd mAbs 559/64-D, 654-D, 729-D, and 9CL se-
lected with rgp120LAI (Karwowska et al., 1992, 1993; Van-
ott et al., 1995), anti-C5 mAb 858-D selected with
gp120LAI (Forthal et al., 1995), and anti-gp41 mAbs 50-69,
98-6, and 167-D, selected on viral lysates of HIVIIIB (Gorny
t al., 1989; Xu et al., 1991). 989-D, a mAb to the distal
pitope of C5 (specific for a peptide spanning amino
cids 510–516) was also used; this mAb was selected on
gp120LAI. The anti-parvovirus B19 human mAb 860-55D
(Gigler et al., 1999) was used as a negative control.
The polyclonal antiserum to HIV-1 gp120 was obtained
through the AIDS Research and Reference Reagent Program
(Division of AIDS, NIAID, NIH) from Dr. Michael Phelan.
Envelope proteins and peptides
Oligomeric gp140 and monomeric gp120 were affinity
purified from cell cultures infected with HIV451 as de-
scribed in detail previously (Kalyanaraman et al., 1988,
1990; VanCott et al., 1995). Briefly, both proteins were puri-
fied from serum-free conditioned medium by affinity chro-
matography using a mouse mAb to HIV-1 gp41 or gp120,
respectively. Structural analysis by gradient centrifuga-
tion, cross-linking, and gel electrophoresis showed that ao.140 occurs as oligomers but not as aggregates (Van-
Cott et al., 1995). The o.140 exists mostly as dimers and
trimers or tetramers (approximately 75%) with some
monomers (VanCott et al., 1995). Oligomeric gp140 from
IIIB was purified similarly (Kalyanaraman et al., 1988,
1990) and was purchased from Advanced BioScience
Laboratories (Kensington, MD). Both oligomers are un-
cleaved and truncated at the C-terminus of the molecule
as shown by sequence analysis; the o.140451 has a length
of 806 amino acids and o.140IIIB, 813 amino acids. Despite
these truncations, these oligomeric glycoproteins were
previously designated as gp160 (Kalyanaraman et al.,
1988, 1990; VanCott et al., 1995).
Recombinant sCD4 and gp120LAI produced in CHO
ells, and gp41IIIB (aa 517–757) and gp41IIIB (aa567–647),
produced in Escherichia coli, were purchased from In-
racel (Issaquah, WA). The recombinant gp41IIIB (aa 517–
757) (m.41) was analyzed by polyacrylamide gel electro-
phoresis (Laemmli, 1970) under nonreducing conditions
and showed only one band stained by silver at 29 kDa.
Glycosylated recombinant gp41HxB2 produced in Pichia
pastoris (aa 546–682) was purchased from Viral Thera-
peutics, Inc. (Ithaca, NY). The recombinant PR6 glyco-
protein from HIVBH10 gp120 with a deleted V1/V2 region
was produced in Chinese hamster ovary cells as re-
cently published (Jeffs et al., 1996) and provided by Dr.
Simon Jeffs.
The V3 peptides of MN, SF2, SC, NY/5, and CDC4 and
two peptides, spanning residues 486–509 and 495–516
from the C-terminus of gp120IIIB, were purchased from
Intracel.
Binding assays
To test the specificity of the newly generated anti-V3
and anti-C5 mAbs selected on o.140, peptides represent-
ing the V3 region and C-terminus, respectively, were
used in the peptide ELISA previously described (Gorny et
al., 1989, 1997).
The specificity of the newly described anti-V2 mAbs
was determined by an ELISA in which mAbs were tested
for their ability to block the binding of biotinylated-anti-V2
mAb 697-D to recombinant gp120 from LAI. mAbs
against the V3 loop (mAb 447-52D) and the CD4bd (mAb
654-D) were used as negative controls in these experi-
ments. MAb 697-D was biotinylated using the EZ-link
Sulfo-NHS-LC-Biotinylation kit (Pierce, Rockford, IL) ac-
cording to the manufacturer’s protocol. In addition, lack
of reactivity of mAbs with the PR6 protein from which the
V1/V2 region was deleted, served as a second assay that
confirmed the specificity of the anti-V2 mAbs.
Anti-CD4bd mAbs were identified by their ability to
inhibit gp120-sCD4 binding as described with some
modifications (Karwowska et al., 1992). Briefly, the test
mAb was incubated together with rgp120LAI and sCD4,
nd subsequently the complex was captured by immo-
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Fallbrook, CA). The presence of sCD4 in such complexes
was detected with murine mAb OKT4 (Ortho, Raritan, NJ)
followed by binding of alkaline phosphatase-conjugated
goat anti-murine IgG antibody (Sigma Chemical Co., St.
Louis, MO).
The specificity of anti-gp41 mAbs was determined by
various binding assays using overlapping recombinant
gp41 proteins and gp41 peptides (Gorny et al., submitted
or publication).
Comparative reactivities of mAb binding to m.120451 ver-
sus o.140451 and to m.41IIIB (aa 517–757) versus o.140IIIB were
assessed by ELISA (Gorny et al., 1989). Each protein
(m.120, m.41, and o.140) was coated onto ELISA plates at 10
nM to standardize their concentrations in the binding assay.
The same amount of m.120 and o.140 was found to bind to
the plates, as the majority of mAbs (Fig. 1) and polyclonal
antiserum to HIV-1 gp120 (data not shown) reacted in ELISA
with similar maximal binding values of 2.0 OD. Slightly
different maximal binding values were attained with m.41
and o.140 when reacted with some of the anti-gp41 mAbs.
These differences would not have obscured changes in the
half-maximal binding due to substantially dissimilar affini-
ties of mAbs. A direct coating technique in an ELISA format
was used as the simplest method of presenting antigens
after it was shown that capturing o.140 by the anti-C-termi-
nus Ab had little effect on antibody reactivity (Richardson et
al., 1996). mAbs at increasing concentrations from 0.003 to
10.0 mg/ml were incubated with coated antigen, and their
inding was determined by applying a secondary poly-
lonal goat antibody to human IgG (g-chain specific) cou-
pled to alkaline phosphatase (Zymed, South San Francisco,
CA), as previously described (Gorny et al., 1989). The con-
entration (mg/ml) of mAb that gave 50% maximal binding
(half-maximal binding) was calculated when the binding
reached the saturation point. The half-maximal binding was
obtained mathematically by linear interpolation using Quat-
tro Pro software (Corel, Ottawa, Canada).
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